​

Jasper Therapeutics (JSPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

JSPR Stock Forecast

Jasper Therapeutics stock forecast is as follows: an average price target of $63.00 (represents a 192.07% upside from JSPR’s last price of $21.57) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

JSPR Price Target

The average price target for Jasper Therapeutics (JSPR) is $63.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $63.00. This represents a potential 192.07% upside from JSPR's last price of $21.57.

JSPR Analyst Ratings

Buy

According to 10 Wall Street analysts, Jasper Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for JSPR stock is 0 'Strong Buy' (0.00%), 10 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Jasper Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Etzer DaroutBMO Capital$63.00$21.53192.61%192.07%
May 06, 2024Emily BodnarH.C. Wainwright$65.00$24.52165.09%201.34%
Apr 03, 2024Gavin Clark-GartnerEvercore ISI$65.00$26.20148.09%201.34%
Feb 07, 2023Cantor Fitzgerald$6.00$1.92212.50%-72.18%
Jan 11, 2023Credit Suisse$3.00$1.6581.82%-86.09%

The latest Jasper Therapeutics stock forecast, released on Dec 05, 2024 by Etzer Darout from BMO Capital, set a price target of $63.00, which represents a 192.61% increase from the stock price at the time of the forecast ($21.53), and a 192.07% increase from JSPR last price ($21.57).

Jasper Therapeutics Price Target by Period

1M3M12M
# Anlaysts113
Avg Price Target$63.00$63.00$64.33
Last Closing Price$21.57$21.57$21.57
Upside/Downside192.07%192.07%198.24%

In the current month, the average price target of Jasper Therapeutics stock is $63.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 192.07% increase as opposed to Jasper Therapeutics's last price of $21.57. This month's average price target is down 0.00% compared to last quarter, and down -2.07% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024BMO CapitalOutperformInitialise
Oct 15, 2024H.C. WainwrightBuyBuyHold
Oct 14, 2024OppenheimerOutperformOutperformHold
Oct 14, 2024BTIGBuyBuyHold
Oct 14, 2024Cowen & Co.BuyBuyHold
Sep 09, 2024JMP SecuritiesOutperformInitialise
Aug 14, 2024RBC CapitalOutperformOutperformHold
Jul 08, 2024BTIGBuyInitialise
Jun 25, 2024OppenheimerOutperformOutperformHold
May 06, 2024H.C. WainwrightBuyInitialise
Apr 03, 2024Evercore ISIOutperformInitialise
Mar 27, 2024RBC CapitalOutperformInitialise
Feb 07, 2023Cantor FitzgeraldOverweightOverweightHold
Nov 14, 2022OppenheimerOutperformOutperformHold
Feb 28, 2022Cantor FitzgeraldOverweightInitialise
Feb 25, 2022Credit SuisseOutperformOutperformHold

Jasper Therapeutics's last stock rating was published by BMO Capital on Dec 05, 2024. The company Initialise its JSPR rating from "null" to "Outperform".

Jasper Therapeutics Financial Forecast

Jasper Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Jasper Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. JSPR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Jasper Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict JSPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Jasper Therapeutics's previous annual EBITDA (undefined) of $NaN.

Jasper Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-16.78M$-16.19M$-15.84M$-15.27M$-19.71M$-18.96M$-17.79M$-18.03M$-18.93M$-16.07M$-16.31M
High Forecast$-16.78M$-16.19M$-15.84M$-15.27M$-19.71M$-18.96M$-17.79M$-14.95M$-16.55M$-16.07M$-16.31M
Low Forecast$-16.78M$-16.19M$-15.84M$-15.27M$-19.71M$-18.96M$-17.79M$-20.96M$-20.27M$-16.07M$-16.31M
Surprise %-----------

Jasper Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. JSPR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Jasper Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Jasper Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to JSPR last annual SG&A of $NaN (undefined).

Jasper Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-1.12$-1.08$-1.06$-1.02$-1.31$-1.26$-1.19$-1.20$-1.26$-1.07$-1.09
High Forecast$-1.12$-1.08$-1.06$-1.02$-1.31$-1.26$-1.19$-1.00$-1.10$-1.07$-1.09
Low Forecast$-1.12$-1.08$-1.06$-1.02$-1.31$-1.26$-1.19$-1.40$-1.35$-1.07$-1.09
Surprise %-----------

According to undefined Wall Street analysts, Jasper Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to JSPR previous annual EPS of $NaN (undefined).

Jasper Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XLOXilio Therapeutics$0.93$7.00652.69%Buy
EPIXESSA Pharma$1.64$9.50479.27%Hold
INZYInozyme Pharma$2.94$16.00444.22%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
JSPRJasper Therapeutics$22.45$63.00180.62%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
ORICORIC Pharmaceuticals$8.25$20.00142.42%Buy
DSGNDesign Therapeutics$6.25$9.6754.72%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
HOOKHOOKIPA Pharma$2.13$3.0040.85%Buy
IKNAIkena Oncology$1.62$1.33-17.90%Buy

JSPR Forecast FAQ

Is Jasper Therapeutics a good buy?

Yes, according to 10 Wall Street analysts, Jasper Therapeutics (JSPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 100.00% of JSPR's total ratings.

What is JSPR's price target?

Jasper Therapeutics (JSPR) average price target is $63 with a range of $63 to $63, implying a 192.07% from its last price of $21.57. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Jasper Therapeutics stock go up soon?

According to Wall Street analysts' prediction for JSPR stock, the company can go up by 192.07% (from the last price of $21.57 to the average price target of $63), up by 192.07% based on the highest stock price target, and up by 192.07% based on the lowest stock price target.

Can Jasper Therapeutics stock reach $30?

JSPR's average twelve months analyst stock price target of $63 supports the claim that Jasper Therapeutics can reach $30 in the near future.

What is Jasper Therapeutics's current price target trend?

1 Wall Street analyst forecast a $63 price target for Jasper Therapeutics (JSPR) this month, up 192.07% from its last price of $21.57. Compared to the last 3 and 12 months, the average price target increased by 192.07% and increased by 198.24%, respectively.

What are Jasper Therapeutics's analysts' financial forecasts?

Jasper Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-74.493M (high $-71.414M, low $-77.424M), average SG&A $0 (high $0, low $0), and average EPS is $-4.966 (high $-4.761, low $-5.161). JSPR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.073M (high $-64.073M, low $-64.073M), average SG&A $0 (high $0, low $0), and average EPS is $-4.271 (high $-4.271, low $-4.271).